Last reviewed · How we verify
NCT03599726
Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil
EARLY_PHASE1 trial testing Donepezil in Parkinson Disease in 20 participants. Completed in 30 July 2019.
30 May 2019
Quick facts
| Lead sponsor | Oregon Health and Science University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 30 July 2018 |
| Primary completion | 30 May 2019 |
| Estimated completion | 30 July 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Donepezil (DONEPEZIL) — full drug profile →
- Placebo
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Oregon Health and Science University
Who can join
Adults 50 to 90, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Safe and independent mobility at home and in the community requires control of walking while accomplishing other functional tasks. A hallmark of healthy control of walking is automaticity, defined as the ability of the nervous system to successfully coordinate movement with minimal use of attention-demanding executive resources \[1\]. Recent evidence indicates that walking disorders are often characterized by a shift in the locomotor control strategy from healthy automaticity to compensatory executive control. This shift is potentially detrimental to walking performance as an executive control strategy is not optimized for locomotor control and it places excessive demands on a limited pool of cognitive reserve. Here, the investigators hypothesize that walking automaticity, as measured by the prefrontal cortex activity while walking, will be improved by donepezil (a cholinesterase inhibitor).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03599726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Donepezil
Trials testing the same drug.
- NCT05592678 — δ in Dementia Clinical Trials · NA · recruiting
- NCT06417086 — Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers · NA · recruiting
- NCT06285240 — Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1 · Phase 1 · completed
- NCT05438264 — Effect of Donepezil on Speech Recognition in Cochlear Implant Users · EARLY_PHASE1 · active not recruiting
- NCT05540977 — Donepezil Prevents Urinary Retention After Extensive Total Hysterectomy · EARLY_PHASE1 · unknown
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Oregon Health and Science University trials
Trials by the same sponsor.
- NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
- NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
- NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
- NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
- NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03599726 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
- Last refreshed: 11 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03599726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing